维普期刊资源整合服务平台（V6.5）

51篇 您的检索式：作者名="HARNETT P"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	New therapies for ovarian cancer: cytotoxics and molecularly targeted agents显示文摘	Dinh P Harnett P Piccart Geb hart MJ	2008	Crit Rev oncol Hematol2008，67，2：	1
2	New therapies for ovarian cancer: cytotoxics and molecularly targeted agents 显示文摘	Dinh P Harnett P Piccart-Gebhart MJ	2008	Crit Rev Oncol Hematol2008，67，2：	1
3	New therapies for ovarian Cancer: cytotoxics and molecularly targeted agents 显示文摘	Dinh P Harnett P Piccart-Gebhart MJ	2008	Crit RevOncolHematol2008，67，2：	1
4	Carboplatin desensitiza- tion显示文摘	CHOI J HARNETT P FULCHER DA	2004	Ann Allergy Asthma Immunol2004，93，2：	1
5	Hypoalbuminemia,cardiac morbidity,and mortality in end-stage renal disease显示文摘	Foley R Parfrey P Harnett J	1996	J Am Soc Nephrol1996，7，5：	1
6	Phase Ⅱ study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer:an Australian and New Zealand Gynaecological Oncology Group study显示文摘	HARNETT P BUCK M BEALE P	2007	Int J Gynecol Cancer2007，17，2：	1
7	The physiologic cipher at altitude:telemedicine and real-time monitoring of climbers on Mount Everest显示文摘	SATAVA R ANGOOD P B HARNETT B		0，，03：	1
8	New therapies for ovarian cancer: cytotoxics and molecularly targeted agents显示文摘	Dinh P Harnett P Piccart-Gebhart MJ	2008	Crit Rev Oncol Hematol2008，67，2：	1
9	Outcome and risk factors for left ventricular disorders in chronic uraemia显示文摘	Palfrey P S Foley R N Harnett J D	1996	Nephrol Dial Transplant1996，11，7：	1
10	Inflammatory mediators in gastroesophageal reflux disease:impact on esophageal motility,fibrosis,and carcinogenesis显示文摘	Rieder F Biancani P Harnett K	2010	Am J Physiol Gastroirtest Liver Physiol2010，298，5：	1
11	The natural history of myocardial diease in dialysis patients显示文摘	PARFREY P S HARNETT J D BARRE P E	1991	J Am Soc Nephrol1991，2，：	1
12	Inflammatory mediators in gastroesophageal reflux disease:impact on esophageal motility,fibrosis,and carcinogenesis显示文摘	Rieder F Biancani P Harnett K		0，，05：	1
13	The clinical course of left ventricular hypertrophy in dialysis patients显示文摘	Parfrey P S Harnett J D Griffiths S M	1990	Nephron1990，55，：	1
14	New therapies for ovarian cancer;cytotoxics and moleculary targeted agents 显示文摘	Dinh P Harnett P Piccart-Gebhart MJ	2008	Crit Rev Oncol Hematol2008，67，2：	1
15	Phase Ⅱ study of Gemcitabineand Oxaliplatin in patients with recurrent ovarian cancer:an Australian and New Zealand Gynaecological Oncology Group study显示文摘	Harnett P Buck M Beale P		0，，02：	1
16	Phase Ⅱ study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer:an australian and new zealand gynaecological oncology group study显示文摘	Harnett P Buck M	2007	Int J Gynecol Cancer2007，17，2：	1
17	New therapies for ovarian cancer: eytotoxics and molecularly targeted agents 显示文摘	Dinh P Harnett P Piccart G	2008	Crit Rev Oncol Hematol2008，67，2：	1
18	Phase II study of gemcitabine and oxaliplatin in patients withrecurrent ovarian cancer:an Australian and New Zealand Gynaecological Oncology Groupstudy显示文摘	Harnett P Buck M Beale P		0，，02：	1
19	Phase II study of Gemcitabine and Oxaliplatin in patients with recurrent ovarian cancer:an Australian and New Zealand Gynaecological Oncology Group study显示文摘	Harnett P Buck M Beale P	2007	Int J Gynecol Canc2007，17，2：	1
20	Phase lI study of gemcitabine and oxalip -latin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study显示文摘	Harnett P Buck M Beale P	2007	Int J Gy- necol Cancer2007，17，2：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示